4Keefe EB, Dieterich DT, Han SH, et al. At reatm entalgorithm for the 1/lan - age ment of chronichep atitis B virus infection in the United States: an update [ J ]. Clin Gastroenteml Helmtol, 2006,4 (8) :936 -962.
二级参考文献7
1Honkoop P, De Man RA. Entecavir: a potent new antiviral drug for hepatitis B. Expert Opin Investig Drugs, 2003, 12: 683-688.
2Seifer M, Hamatake RK, Colonno RJ, et al. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475and lobucavir. Antimicrob Agents Chemother, 1998, 42: 3200-3208.
3de Man RA, Wolters LM, Nevens F, et al. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology, 2001, 34: 578-582.
4Lai CL, Rosmawati M, Lao J, et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology, 2002, 123: 1831-1838.
5Marion PL, Salazar FH, Winters MA, et al. Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication. Antimicrob Agents Chemother, 2002, 46: 82-88.
6Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol, 2005, 42: 302-308.
